Identification of ANKRD11 as a p53 coactivator
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The ability of p53 to act as a transcription factor is critical for its function as a tumor suppressor. Ankyrin repeat domain 11, ANKRD11 (also known as ANR11 or ANCO1), was found to be a novel p53-interacting protein that enhanced the transcriptional activity of p53. ANKRD11 expression was shown to be downregulated in breast cancer cell lines. Restoration of ANKRD11 expression in MCF-7 (wild-type p53) and MDA-MB-468 (p53R273H mutant) cells suppressed their proliferative and clonogenic properties through enhancement of CDKN1A (p21waf1/CIP1) expression. ShRNA-mediated silencing of ANKRD11 expression reduced the ability of p53 to activate CDKN1A expression. ANKRD11 was shown to associate with the p53 acetyltransferases and cofactors, P/CAF and hADA3. Exogenous ANKRD11 expression enhanced the levels of acetylated p53 in both MCF-7 and MDA-MB-468 cells. ANKRD11 enhanced the DNA-binding properties of mutant p53R273H to the CDKN1A promoter, suggesting that ANKRD11 can mediate the restoration of normal p53 function in some cancer-related p53 mutations. In addition, ANKRD11 itself was found to be a novel p53 target gene. These findings demonstrate a role for ANKRD11 as a p53 coactivator and suggest the involvement of ANKRD11 in a regulatory feedback loop with p53.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · cited 1×
“The p53 protein is the most important tumor suppressor in the cell and is described as ‘the guardian of the genome’ (Lane, 1992).”
BackgroundRequirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · cited 1×
“HCT116 and its TP53–/– derivative were supplied by B. Vogelstein (Bunz et al., 1998).”
MethodRegulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
DNA damage activates p53 through a phosphorylation–acetylation cascade
Sakaguchi, K., Herrera, J. E., Saito, S., Miki, T., Bustin, M., Vassilev, A., Anderson, C. W., & Appella, E. (1998) · Genes & Development · doi:10.1101/gad.12.18.2831 · Cited by 1,204 · cited 2×
“Earlier studies have shown that acetylation of p53 promotes its ability to bind its cognate DNA-response element in vitro (Gu and Roeder, 1997; Sakaguchi et al., 1998); however, these findings are not consistent with recent in vivo data (Liu and Chen, 2006; Tang et al., 2008; Toledo and Wahl, 2006).”
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 2×
“Rescue of DNAcontact mutants has been demonstrated through restoration of their DNA-binding affinities following treatment with a p53-derived Cterminal peptide (Selivanova et al., 1997), small p53-activating molecules (CP-257042, CP-31398 and PRIMA-1) (Bykov et al., 2002; Foster et al., 1999) or the introduction of se…”
InfluentialAcetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838
Acetylation of the p53 DNA-binding domain regulates apoptosis induction.
Sykes, S. M., Mellert, H. S., Holbert, M. A., Li, K., Marmorstein, R., Lane, W. S., & McMahon, S. B. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.026 · Cited by 752 · cited 1×
“The acetylation of specific lysine residues of p53 is mediated by several acetyltransferases, including p300/CBP (Lys164, Lys370, Lys372, Lys373, Lys381, Lys382 and Lys386), Tip60/hMOF (Lys120) and P/CAF (Lys320) (Gu and Roeder, 1997; Sakaguchi et al., 1998; Sykes et al., 2006; Tang et al., 2008).”
Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710 · cited 2×
“The p53-K320R mutant was generated from the p53-K320/373/381/382R construct supplied by Shelly Berger (Barlev et al., 2001).”
Method
Cited by
p53, Oxidative Stress, and Aging
Liu, D., & Xu, Y. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3644 · Cited by 316
Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma
Pishas, K. I., Al-Ejeh, F., Zinonos, I., Kumar, R., Evdokiou, A., Brown, M. P., Callen, D. F., & Neilsen, P. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1587 · Cited by 71
Self-citationMills, M., Emori, C., Kumar, P., Boucher, Z., George, J., & Bolcun-Filas, E. (2025) · Developmental Biology · doi:10.1016/j.ydbio.2024.09.007 · Cited by 12
Dysfunction of a SET3-like complex underlies a family of related neurological disorders
Paton, K. M., Alexander-Howden, B., Hare, J. I., Guy, J., Chhatbar, K., Yudina, M., Morris, S. T., Walls, R., Mathieson, T., Spanos, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73227-5
Metadata
- Authors
- Neilsen, P. M., Cheney, K. M., Li, C.-W., Chen, J. D., Cawrse, J. E., Schulz, R. B., Powell, J. A., Kumar, R., & Callen, D. F.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2008-11-01
- Volume
- 121
- Issue
- 21
- Pages
- 3541-3552
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W2078744165
- Cited by
- 93
- References
- 9
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.